Skip to main content

Table 1 Baseline characteristics of treatment groups.

From: Safety and Effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial

  Tranexamic acid P
  TA1 group
(40-0 mg/Kg)
(n = 80)
TA2 group
40-40 mg/Kg
(n = 80)
 
Demographics    
Age (years) 65 (62-69) 68 (65-70) 0.24
Male sex, n (%) 54 (67.5) 49 (61.3) 0.41
Parsonnet 9.2 (7.2-11.2) 10.5 (8.4-12.5) 0.30
Euroscorea 4 (3-6) 4 (3-7) 0.38
Logistic Euroscorea 3.25(1.83-5.53) 3.27(1.75-6.68) 0.84
Body mass index (Kg/m2) 28.2 (27.4-29) 27.7 (26.6-28.8) 0.50
Comorbidity    
Hypertension, n (%) 43 (53.8) 53 (66.3) 0.11
Diabetes, n (%) 36 (45) 28 (35) 0.42
Medical treatment    
Angiotensin-converting enzyme inhibitors, n (%) 28 (35) 22 (27.5) 0.31
Preoperative parameters    
Platelet count (× 103 ml-1) 247 (227-267) 262 (239-285) 0.48
D-dimer (ng/ml) 347 (217-476) 287 (221-353) 0.95
International normalized ratio 1.04 (1-1.07) 1.05 (1.01-1.09) 0.28
Cardiac intervention    
Coronary, n (%) 45 (56.3) 39 (48.8) 0.51
Valvular, n (%) 25 (31.3) 31 (38.8)  
Both, n (%) 9 (11.3) 7 (8.8)  
Other, n (%)b 1 (1.3) 3 (3.8)  
Second intervention, n (%) 4 (5) 3 (3.8) 0.51
Surgical data    
Temperature during cardiopulmonary bypass (°C) 32.3 (32-32.5) 32.3 (32.1-32.5) 0.78
Aortic clamp time (min) 53 (49-58) 51 (46-57) 0.61
Cardiopulmonary bypass time(min) 88 (82-94) 84 (77-92) 0.45
Temperature after cardiopulmonary bypass (°C) 35.5 (35.3-35.6) 35.7 (35.5-35.8) 0.03
Total heparin dose (UI/Kg) 391 (371-412) 400 (379-421) 0.56
Total protamine dose (mg/Kg) 2.7 (2.6-2.8) 2.9 (2.8-3.1) 0.04
Heparine/protamine 1.45 (1.37-1.53) 1.39 (1.33-1.44) 0.29
Blood salvage (ml) 724 (663-784) 703 (636-767) 0.64
  1. Values expressed as mean and 95% confidence interval; frequencies and percentages; amedian and percentiles.
  2. bInter-atrial communication.